CliffBio
small molecule

VIMPAT

LACOSAMIDE

Loss of exclusivityApril 2026FDA regulatory exclusivity expiry
CompanyUCB →See this company's full patent-cliff portfolio

Drug detail

Brand nameVIMPAT
Active ingredientLACOSAMIDE
Strength100MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalOctober 2008
Marketing statusRX

Regulatory exclusivity

CodeExpires
D-188April 2026

More from UCB

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.

VIMPAT patent cliff — loss of exclusivity April 2026 | CliffBio